ArticleBlood cancer journal2026

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Andrew J Portuguese et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.